Vaccinology has had wonderful successes over the last 200 years since Edward Jenner first used animal poxvirus to prevent smallpox in humans [1]. Vaccines have been developed in 2 broad categories: live attenuated and killed inactivated, both yielding powerfully protective preventives. However, those successes have often come by chance after laborious and long development depending on best guesses and good fortune. Toward the end of the last century, methods for vaccine development evolved toward predictable techniques that allow for better design and more rapid development. One term for this is “precision vaccinology,” the subject of the articles in this supplement of Clinical Infectious Diseases [2].

Vaccine development initially and even now is focused on diseases that are difficult to treat and for which prevention is the best strategy. Although many endemic infections fall into this category, one must admit that epidemics of disease have often been the stimulus for vaccine development. The human species has been the host for innumerable endemic infections such as smallpox and malaria, but only some have caused devastating pandemics that threatened civilization. Many of those are listed in Table 1 and described in books [3]. Although in some cases a hundred years have passed between epidemics such that human memory had forgotten the prior ones, the fact is that humanity has been a fertile host for microbial outbreaks, and if anything, they are more frequent now than ever before thanks to greater human mobility and contact.

For most of the history of vaccinology, vaccines have consisted of killed organisms that caused a disease, or organisms weakened by being passaged in unnatural environments until they lost pathogenicity. It was the advent of molecular biology and genetic engineering that enabled us to create potent vaccines with more specificity. Table 2 lists strategies for development of inactivated nonliving vaccines beyond simple killing. Capsular polysaccharides conjugated chemically to proteins become potent at preventing bacteria that rely on those polysaccharides to evade host defenses [4]. Analysis of proteins coded by bacterial genomes allows selection of important antibody-producing proteins [5]. Structural analysis enables selection of proteins that induce protective responses. A whole host of adjuvants that stimulate Toll-like receptors are now being used to replace simple aluminum salts [6]. Nucleic acids coding for important proteins, both messenger RNA and DNA, can now be used to synthesize proteins important for protection [7, 8].

New strategies to develop live vaccines are listed in Table 3. Reassortment of genes for viral proteins was used to develop a vaccine against rotavirus infantile diarrhea [9]. In addition, deleting genes from viruses to attenuate their virulence achieves rapid attenuation, as does recombining genes from virulent and attenuated organisms. Vectors such as adenovirus or vesicular stomatitis virus can carry genes from pathogens and express their protective proteins. More directly, sequences of nucleic acids that code for important antigens can be changed so that the living organism is attenuated and useful as a vaccine.

Despite the great success of vaccines in this century, typified by the high efficacy of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), we must admit that important problems remain. For example, the efficacy of

### Table 1. Epidemics of the Past

| Date | Epidemic                      |
|------|-------------------------------|
| 430 BC | Plague of Athens              |
| 160 AD | Plague of Antonine            |
| 542 AD | Plague of Justinian           |
| 1340 AD | The Medieval Plague          |
| 1500 AD | Plague of the Incas           |
| 1665 AD | Great Plague of London        |
| 1793 AD | Yellow fever                  |
| 1832 AD | Cholera                      |
| 1918 AD | Influenza                     |
| 20th–21st century | Ebola, HIV, swine flu, chikungunya, Zika, COVID-19 |

Abbreviations: COVID-19, coronavirus disease 2019; HIV, human immunodeficiency virus.
acellular pertussis vaccines wane with time after vaccination of infants, influenza vaccines have only modest efficacy, and there are as yet no licensed vaccines against respiratory syncytial virus (RSV) or human immunodeficiency virus.

With respect to pertussis, replacement of chemically inactivated pertussis toxin with genetically inactivated pertussis toxin allows persistence of epitopes that induce higher efficacy [10].

Influenza vaccines may be improved by the addition of stalk antigens as well as the heads of the hemagglutinin molecules [11]. RSV vaccines for the elderly will certainly be improved by stabilizing the prefusion F antigen of the virus, whereas new mutated RSV strains may provide protection for infants [6, 12].

Other problems worth mentioning include the difficulty of developing a vaccine against herpesviruses including herpes simplex virus, human cytomegalovirus, and Epstein-Barr virus. The reasons for this include the cell association of the viruses and the importance of generating Fc effector functioning antibodies as well as neutralizing antibodies. On the other hand, vaccines against cancers induced by viruses are promising [13].

The race to produce vaccines against SARS-CoV-2 illustrates the advances in vaccinology. Table 4 lists some of the factors that allowed rapid development and deployment of vaccines, which also provide hope for the future of vaccinology, despite the resistance to vaccination that has been problematic in certain less progressive areas of the United States. The features that allowed for rapid development of vaccines against the new virus include knowledge concerning the mechanism of attachment and entry of coronaviruses into human cells, the presence of the receptor-binding domain in the spike protein that is the chief inducer of neutralizing antibodies, and the evident correlation of neutralizing antibodies with efficacy [14]. In addition, the profound and effective response of the vaccine industry to the emergency has been striking and unprecedented.

---

**Table 2. New Strategies for Inactivated Vaccine Discovery**

| Strategy                                                                 |
|--------------------------------------------------------------------------|
| Protein-conjugated capsular polysaccharides                             |
| Reverse vaccinology                                                      |
| Antigen identification by transcriptomics and proteomics                 |
| Structural analysis                                                      |
| Development of new adjuvants (including cytokines)                      |
| DNA plasmids                                                             |
| mRNA and self-amplifying RNA                                            |

Abbreviation: mRNA, messenger RNA.

---

**Table 3. New Strategies for Attenuated Vaccine Discovery**

| Strategy                                                                 |
|--------------------------------------------------------------------------|
| Temperature-sensitive mutations and reassortment                          |
| Viral recombinants and deletion mutants                                   |
| Codon de-optimization                                                     |
| Vectors that present genes from pathogens                                 |

---

**Table 4. What Is New About Vaccination for Coronavirus Disease 2019**

| What Is New About Vaccination for Coronavirus Disease 2019               |
|-------------------------------------------------------------------------|
| Desire of public for vaccination                                         |
| Multiple strategies used for vaccine development                        |
| Financial support by governments                                        |
| Importance of mutations, as in influenza                                 |
| Multiple manufacturers, including in low- and middle-income countries    |

---

**Table 5. Unsolved Problems in Vaccinology**

| Problem                                      | Solution                                  |
|----------------------------------------------|-------------------------------------------|
| Immune memory                                | More stimulus of Tfh cells                |
| Role of IL-7?                                | Stronger induction of innate immunity by TLR agonists |
| Multiplicity of virulence antigens in complex pathogens | Antigenomics—analysis of natural immune responses |
| Multiple HLA types                           | Polypeptide vaccines                      |
| Conserved epitopes                           | Structural biology                         |
| Finding correlates of protection            | Systems biology                           |
| Immaturity and postmaturity of the immune system | Add cytokines or                           |
|                                             | neutralize cytokines?                      |
| Mucosal immunization with nonreplicating antigens | Use nanoemulsions?                      |
| Adjuvants capable of selectively expanding cell types: dendritic, B, Th1, Th2, Th17, CD4+, CD8+, or Tregs | Use single or combined                     |
| TLR ligands?                                |                                          |
| The difficulty to generate T-cell immunity without replicating vaccines | Adjuvants?                                |

Abbreviations: HLA, human leukocyte antigen; IL-7, interleukin 7; Tfh, T follicular helper; TLR, Toll-like receptor; Tregs, regulatory T cells.

---

**Table 6. Some Features of the Future of Vaccinology**

| Feature                                      |
|----------------------------------------------|
| Influenza—vaccine addition of neuraminidase and stalk |
| RSV—structural analysis of antigens           |
| Attenuation by mutation of genomes            |
| Nanoparticles                                 |
| Messenger and self-amplifying RNA            |
| Vectors carrying vaccine antigens             |
| Induction of Fc receptor antibodies           |
| Vaccines for the elderly                      |
| Manufacture in developing countries          |

Abbreviation: RSV, respiratory syncytial virus.
However, numerous problems remain in the field of vaccinology, some of which are listed in Table 5, together with possible solutions. Fortunately, the advance of science in this century has been striking, leading to optimism about the future. Table 6 lists some of the favorable developments that lead to the hope that by the year 2100 vaccinology will be triumphant against both infectious and noninfectious diseases.

Notes

Supplement sponsorship. This supplement is sponsored by the Precision Vaccines Program of Boston Children’s Hospital.

Potential conflicts of interest. S. A. P. serves as a consultant for Merck, Moderna, New Link, Novavax, Omvax, Takeda, X-Vax, NTx, Valneva, Vaxart, Sanofi, and GSK.

The author has submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

1. Plotkin S. A short history of vaccination. Plotkin’s vaccines. 7th ed. Philadelphia, PA: Elsevier, 2018:1–15.
2. Borriello F, van Haren SD, Levy O. First International Precision Vaccines Conference: multidisciplinary approaches to next-generation vaccines. mSphere 2018; 3:e00214–18.
3. Harper K. Plagues upon the earth: disease and the course of human history. The Princeton economic history of the Western world series. Princeton, NJ: Princeton University Press, 2021.
4. Lucinde RK, Ong’ayo G, Houlihan C, et al. Pneumococcal conjugate vaccine dose-ranging studies in humans: a systematic review. Vaccine 2021; 39:5095–105.
5. Dalsass M, Brozzi A, Medini D, Rappuoli R. Comparison of open-source reverse vaccinology programs for bacterial vaccine antigen discovery. Front Immunol 2019; 10:113.
6. Graham BS, Gilman MSA, McLellan JS. Structure-based vaccine antigen design. Annu Rev Med 2019; 70:91–104.
7. Gary EN, Weiner DB. DNA vaccines: prime time is now. Curr Opin Immunol 2020; 65:21–7.
8. Pardi N, Weissman D. Development of vaccines and antivirals for combating viral pandemics. Nat Biomed Eng 2020; 4:1128–33.
9. Clark HF, Borian FE, Bell LM, Modesto K, Gouvea V, Plotkin SA. Protective effect of WCI vaccine against rotavirus diarrhea in infants during a predominantly serotype 1 rotavirus season. J Infect Dis 1998; 158:570–87.
10. Gregg KA, Merkel TJ. Pertussis toxin: a key component in pertussis vaccines? Toxins (Basel) 2019; 11:557.
11. Krammer F, Weir JP, Engelhardt O, Katz JM, Cox RJ. Meeting report and review: immunological assays and correlates of protection for next-generation influenza vaccines. Influenza Other Respir Viruses 2020; 14:237–43.
12. Vekemans J, Moorthy V, Giessing B, et al. Respiratory syncytial virus vaccine research and development: World Health Organization technological roadmap and preferred product characteristics. Vaccine 2019; 37:7394–5.
13. Maeng HM, Berzoński JA. Strategies for developing and optimizing cancer vaccines. F1000Res 2019; 8:F1000 Faculty Rev–654. doi:10.12688/f1000research.18693.1.
14. Earle KA, Ambrosino DM, Fiore-Garlant A, et al. Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine 2021; 39:4423–8.